Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer
Phase 1/2 Evaluation of Adenoviral p53 (Ad-p53) in Combination With Capecitabine (Xeloda) or Anti-PD-1 in Patients With Unresectable Liver Metastases of Colorectal Carcinoma(CRC) and Other Solid Tumors, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) and Primary Hepatic Cancers With Known Disease Progression on Standard Therapy
Sponsor: MultiVir, Inc.
This PHASE1/PHASE2 trial investigates Metastatic Solid Tumor Cancer and Recurrent Head and Neck Cancer and is currently terminated or withdrawn. MultiVir, Inc. leads this study, which shows 11 recorded versions since 2018 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
-
Jul 2020 — Jan 2021 [monthly]
Terminated PHASE1_PHASE2
Status: Recruiting → Terminated
-
Apr 2019 — Jul 2020 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
▶ Show 6 earlier versions
-
Sep 2018 — Apr 2019 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Jul 2018 — Sep 2018 [monthly]
Not Yet Recruiting PHASE1_PHASE2
Status: Recruiting → Not Yet Recruiting · Phase: PHASE1 → PHASE1_PHASE2
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE1
-
May 2017 — Jun 2018 [monthly]
Recruiting PHASE1
-
Feb 2017 — May 2017 [monthly]
Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- MultiVir, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .